Rare Kidney Diseases Market Landscape 2025: Forecast Data and Growth Strategy Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Rare Kidney Diseases Market Through 2025?
The market size for rare kidney diseases has seen rapid expansion lately. The forecast shows that it will increase from $2.76 billion in 2024 to $3.06 billion in 2025, progressing at a compound annual growth rate (CAGR) of 10.6%. The significant growth during the previous period is attributable to factors such as heightened recognition of the disease, granting of orphan drug designations, patient advocacy and increased awareness, along with worldwide research collaborations.

What's the Projected Size of the Global Rare Kidney Diseases Market by 2029?
In the upcoming years, the market size for rare kidney diseases is anticipated to undergo swift expansion. The market is forecasted to reach $4.49 billion in 2029, with a compound annual growth rate (CAGR) of 10.1%. The projected growth in this duration is due to factors such as the advent of gene therapies, amplified investment in research for rare diseases, increased partnerships among key players, and worldwide endeavors for rare diseases. The forecasted period will witness key trends such as a focus on patient-centricity, utilization of real-world evidence and data analytics, advancements in regulatory practices, telemedicine and remote patient monitoring, as well as emphasis on global health campaigns.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Top Growth Drivers in the Rare Kidney Diseases Industry: What's Accelerating the Market?
Anticipated advancements in the rare kidney disease market are being bolstered by government efforts and financial support dedicated to kidney disorders. This kind of monetary aid from the government is typically allocated to specific groups leading projects or generating ideas that bring enhancements to public services and bolster the economy. Targets selected for this support include entities working to improve the lives of individuals suffering from various kidney conditions through enhanced medical surveillance and a holistic public health strategy. Collaborations with other public health agencies and national bodies are also a part of this plan. A concrete example of this can be seen in July 2022, when the United States House Committee on Appropriations initiated numerous investment projects focusing on kidney health. Among these initiatives was an award of $8.5 million for the Centers for Disease Control and Prevention's chronic kidney disease initiative, aiming to amplify activities centered around regular awareness, diagnosis, and treatment of kidney diseases. Furthermore, an additional $1 million was invested in the National Living Donor Assistance Center to boost living donations, cumulating to an $8 million continuous investment in innovation and research in this area. Consequently, these government efforts and fiscal contributions towards kidney condition management are stimulating the growth and evolution of the rare kidney disease market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11908&type=smp

What Trends Will Shape the Rare Kidney Diseases Market Through 2029 and Beyond?
Prominent market players are increasingly focusing on product innovation within the rare kidney disease market, which is a core trend currently on the rise. Major companies are aiming to bolster their market position by inventing new, ground-breaking products. A prime example of this came in September 2022, when STADA Arzneimittel AG, a company based in Germany that specializes in generics, specialty pharma, and over-the-counter consumer health products, launched Kinpeygo (budesonide). This drug is the first of its kind to gain authorization in the EU for the treatment of a rare kidney disease known as immunoglobulin A nephropathy (IgAN). These reformulated budesonide capsules are the only approved treatment in the EU dedicated to primary IgAN, a rare kidney disease that gradually progresses due to autoimmune malfunctions, leaving a significant unmet medical need. Ultimately, this condition leads to terminal kidney failure in 25-30% of patients, necessitating either dialysis or a kidney transplant.

What Are the Main Segments in the Rare Kidney Diseases Market?
The rare kidney diseases market covered in this report is segmented -

1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications
2) By Type Of Molecule: Small Molecules, Biologics
3) By Route Of administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:
1) By IgA Nephropathy: Immunosuppressive Therapy, Supportive Care And Symptomatic Management
2) By Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics
3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents
4) By Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies
5) By C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies
6) By Other Target Indications: Alport Syndrome, Thin Basement Membrane Nephropathy, Other Rare Kidney Disorders

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11908&type=smp

Which Top Companies are Driving Growth in the Rare Kidney Diseases Market?
Major companies operating in the rare kidney diseases market include Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc., Savara Inc.

Which Regions Will Dominate the Rare Kidney Diseases Market Through 2029?
North America was the leading region in the rare kidney disease market in 2024. The regions covered in the rare kidney diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11908

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.